Minneapolis Clinic of Neurology | Golden Valley, MN
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). Approximately 946 participants will be enrolled and will be recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
OLE Inclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
985 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: GN41791 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal